Cargando…
Juvenile Huntington’s Disease and Other PolyQ Diseases, Update on Neurodevelopmental Character and Comparative Bioinformatic Review of Transcriptomic and Proteomic Data
Polyglutamine (PolyQ) diseases are neurodegenerative disorders caused by the CAG repeat expansion mutation in affected genes resulting in toxic proteins containing a long chain of glutamines. There are nine PolyQ diseases: Huntington’s disease (HD), spinocerebellar ataxias (types 1, 2, 3, 6, 7, and...
Autores principales: | Świtońska-Kurkowska, Karolina, Krist, Bart, Delimata, Joanna, Figiel, Maciej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281051/ https://www.ncbi.nlm.nih.gov/pubmed/34277598 http://dx.doi.org/10.3389/fcell.2021.642773 |
Ejemplares similares
-
Coaggregation of polyglutamine (polyQ) proteins is mediated by polyQ-tract interactions and impairs cellular proteostasis: Coaggregation of polyQ proteins
por: Hong, Jun-Ye, et al.
Publicado: (2023) -
Allele-specific quantitation of ATXN3 and HTT transcripts in polyQ disease models
por: Joachimiak, Paweł, et al.
Publicado: (2023) -
Mouse polyQ database: a new online resource for research using mouse models of neurodegenerative diseases
por: Szlachcic, Wojciech J., et al.
Publicado: (2015) -
Prolyl oligopeptidase inhibition reduces PolyQ aggregation and improves cell viability in cellular model of Huntington’s disease
por: Norrbacka, Susanna, et al.
Publicado: (2019) -
Alleviating neurodegeneration in Drosophila models of PolyQ diseases
por: Long, Zhe, et al.
Publicado: (2014)